SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Washington DC, USA at the Tidal Basin during spring season at night.
Cell Therapy
CAR T for Lupus Takes Center Stage at ACR 2024
Investigational CAR T therapies stole the spotlight at the American College of Rheumatology Convergence as data presented by Bristol Myers Squibb, Kyverna Therapeutics and more highlighted their potential to effectively treat lupus.
November 19, 2024
 · 
4 min read
 · 
Kate Goodwin
Businessman jump careful on cracked or broken graph. Job opportunity and career. concept of under pressure. risk, financial, and tax
Pipeline
Neurogene Drops Batten Gene Therapy Program
After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells investors that it’s evaluating options for the program.
November 19, 2024
 · 
2 min read
 · 
Kate Goodwin
Crowdfunding concept with money icon and human hands in retro 80s collage mixed media vector illustration. Idea for financing business project, funding, philanthropy, cooperation, bank credit and startup development.
Business
Fledgling Obesity Biotech Metsera Raises Another $215M for Long-Acting GLP-1
Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a continued appetite for these drugs.
November 13, 2024
 · 
2 min read
 · 
Kate Goodwin
Facade of AstraZeneca's office in Shanghai, China
Earnings
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the “important” U.S. market.
November 12, 2024
 · 
3 min read
 · 
Kate Goodwin
Neurons sending pulsating electric impulses and communicating with each other. Concept For Neurological Diseases, Tumors And Brain Surgery
Huntington’s
5 Huntington’s Therapies to Watch
A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win. Here, BioSpace looks at five candidates that could change the trajectory for patients.
November 11, 2024
 · 
5 min read
 · 
Kate Goodwin
Madrid, Spain cityscape at Calle de Alcala and Gran Via.
Alzheimer’s
Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s Disease conference focused on the role these drugs might play, as well as combination therapies and innovative new treatment options.
November 11, 2024
 · 
6 min read
 · 
Kate Goodwin
Illustration of abstract tunnel with haematocytes
Drug development
5 Sickle Cell Therapies to Watch Following Pfizer’s Oxbryta Exit
In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.
October 21, 2024
 · 
4 min read
 · 
Kate Goodwin
Set of two dart targets with arrow and dart. Vector color illustration.
Cancer
With Myriad Recent Approvals in Cancer, The Era of Bispecifics Is Here
As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say the class could overtake monoclonal antibody Keytruda as the “immunotherapy backbone” of solid tumor treatment.
October 14, 2024
 · 
6 min read
 · 
Kate Goodwin
Man inside a boat made with a dollar
M&A
Concentra Spies New Target After Kezar’s Lupus Trial Hold
After four patient deaths, Kezar’s lupus trial is officially on hold, sparking investor Kevin Tang’s interest for acquisition.
October 9, 2024
 · 
1 min read
 · 
Kate Goodwin
South San Francisco, CA, USA - May 1, 2022: Exterior view of the Merck Researches Laboratories in South San Francisco, California. Merck & Co., Inc. is a global pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme (MSD) outside the United States and Canada.
Drug Development
Keytruda Redeems Itself in Head and Neck Cancer as Merck Lands Potential $1.9B I&I Collab
On the heels of Keytruda’s success in a Phase III perioperative trial for a disease where it had previously failed to improve event-free survival, Merck touts an I&I deal with UK biotech Mestag.
October 8, 2024
 · 
2 min read
 · 
Kate Goodwin
Psychedelic Brain
Psychedelics
MDMA Drug Developers Reprioritize Following Lykos Rejection in PTSD
After the FDA declined to approve Lykos Therapeutics’ MDMA-assisted therapy for post-traumatic stress disorder, companies are pivoting away from or delaying similar therapeutics targeting the psychiatric disease.
September 30, 2024
 · 
5 min read
 · 
Kate Goodwin
Pictured: Exterior view of the headquarters of the
FDA
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD
Already approved in six indications, Sanofi and Regeneron can now add chronic obstructive pulmonary disease to the list for their blockbuster injection.
September 27, 2024
 · 
2 min read
 · 
Kate Goodwin
A monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Coronavirus. 3d render
Lung cancer
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell lung cancer, but experts stress the need for diverse and overall survival data.
September 18, 2024
 · 
5 min read
 · 
Kate Goodwin
Entrance of the FTC in Washington, DC
Business
Express Scripts Sues FTC, Demands Withdrawal of ‘False and Misleading’ PBM Report
Pharmacy benefit manager Express Scripts announced Tuesday it has filed a lawsuit in federal court in Missouri against the Federal Trade Commission for its “unfair, biased and erroneous” July report on the industry.
September 17, 2024
 · 
2 min read
 · 
Kate Goodwin
Fashionable halftone collage. Concept of wealth, saving, saving and saving money. Money bag with dollar stacks and stacks of coins. Vector illustration of business and finance for web banner, social media banner, marketing material. Vector illustration
Funding
Terns Announces $125M Raise on Heels of Oral GLP-1 Data Drop
Phase I data for TERN-601 suggests Terns’ oral GLP-1 candidate for obesity could be a contender in the market next to big names like Lilly, Pfizer and Roche.
September 10, 2024
 · 
1 min read
 · 
Kate Goodwin
Load More